We are live on ! Find out more

OSRH

OSR Health

OSRH

Market cap $4.09M

Delisted

OSRH was delisted on the 25th of August, 2026.

Back to rankings

About: OSR Health Inc is a healthcare holding company focused on biomedical technologies in health and wellness. Through its subsidiaries, the company engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes across various countries.

Employees: 22

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. To OSR Health Shareholders: I am aware that many of you are watching closely to see what comes next.

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Hearing Request The Company intends to request a hearing before the Nasdaq Independent Hearings Panel (the "Panel") to appeal the Staff Determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. Dear Shareholders, Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program. The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma. Prof. Wolfgang Wick, M.D.

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication with the Company that the Company's Shareholder Loyalty Contingent Value Rights (CVR) program will not result in any mechanical adjustment to the price of OSR Health's common stock - either upon the distribution of the CVRs or upon the delivery of additional shares of common stock to enrolled holders under the program. What this means for shareholders: No mechanical price adjustment.

OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

OSR Health, A Message From the CEO

BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders. To Every OSR Health Shareholder: OSR Health is at an inflection point - one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market.

OSR Health, A Message From the CEO

Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split.

Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares

Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026.

OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares

See News Rankings

Price charts implemented using Lightweight Charts™